A systems biology consideration of the vasculopathy of sickle cell anemia: The need for multi-modality chemo-prophylaxis

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 4, 2009, Pages 271-292

  Hebbel, Robert P ^a   Vercellotti, Greg M ^a   Nath, Karl A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHELATING AGENT; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; L 4F; NITRIC OXIDE; SALAZOSULFAPYRIDINE; TOCOPHEROL DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; VASODILATOR AGENT; VORINOSTAT;

BIOAVAILABILITY; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; ENDOTHELIUM CELL; GENETIC POLYMORPHISM; HEMOLYTIC ANEMIA; HUMAN; INTRAVASCULAR HEMOLYSIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; OXIDATION; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA; TRANSACTIVATION; VASCULAR DISEASE; VASCULARIZATION;

EID: 72449211881     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X10909040271     Document Type: Review

References (124)

1. Hebbel, R.P. In Hematology: Basic Principles and Practice. Eds.; Hoffman, R.; Benz, Jr. E.J.; Shattil, S.J.; Furie, B.; Cohen, H.J.; Silberstein, L.E.; McGlave, P.; Elsevier Churchill Livingstone: Pennsylvania, 2005; pp. 591-604.
2. Embury, SH.; Hebbel, R.P.; Mohandas, N.; Steinberg, M.H.; Eds. Sickle Cell Disease: Basic Principles and Clinical Practice. Raven Press: New York, 1994.
3. Prengler, M.; Pavlakis, S.G.; Prohovnik, I.; Adams, R.J. Sickle cell disease: the neurological complications. Ann. Neurol., 2002, 51, 543-552. (Pubitemid 34438692)
4. Gladwin, M.T.; Sachdev, V.; Jison, M.L.; Shizukuda, Y.; Plehn, J.F.; Minter, K.; Brown, B.; Coles, W.A.; Nichols, J.S.; Ernst, I.; Hunter, L.A.; Blackwelder, W.C.; Schechter, A.N.; Rodgers, G.P.; Castro, O.; Ognibene, F.P. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med., 2004, 350, 886-895. (Pubitemid 38252536)
5. Haque, A.K.; Gokhale, S.; Rampy, B.A.; Adegboyega, P.; Duarte, A.; Saldana, M.J. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum. Pathol., 2002, 33, 1037-1043. (Pubitemid 35215849)
6. Hebbel, R.P.; Osarogiagbon, R.; Kaul, D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation, 2004, 11, 129-151. (Pubitemid 39619075)
7. Hillery, C.A.; Panepinto, J.A. Pathophysiology of stroke in sickle cell disease. Microcirculation, 2004, 11, 195-208. (Pubitemid 39619079)
8. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420, 868-874.
9. Mestas, J.; Ley, K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends. Cardiovasc. Med., 2008, 18, 228-232.
10. Subbanagounder, G.; Wong, J.W.; Lee, H.; Faull, K.F.; Miller, E.; Witztum, J.L.; Berliner, J.A. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J. Biol. Chem., 2002, 277, 7271-7281.
11. Aird, W.C., Ed. Endothelial Biomedicine. Cambridge University Press: New York, 2007.
12. Eaton, W.A.; Hofrichter, J. Hemoglobin S gelation and sickle cell disease. Blood, 1987, 70, 1245-1266. (Pubitemid 18026123)
13. Christoph, G.W.; Hofrichter, J.; Eaton, W.A. Understanding the shape of sickled red cells. Biophys. J., 2005, 88, 1371-1376.
14. Coletta, M.; Hofrichter, J.; Ferrone, F.A.; Eaton, W.A. Kinetics of sickle hemoglobin polymerization in single red cells. Nature, 1982, 300, 194-197.
15. Ferrone, F.A. In Sickle Cell Disease: Basic Principles and Clinical Practice. Embury, S.H.; Hebbel, R.P.; Mohandas, N.; Steinberg, M.H.; Eds.; Raven Press: New York, 1994.
16. Mozzarelli, A.; Hofrichter, J.; Eaton, W.A. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science, 1987, 237, 500-506.
17. Mohandas, N.; Hebbel, R.P. In Sickle Cell Disease: Basic Principles and Clinical Practice. Eds.; Embury, S.H.; Hebbel, R.P.; Steingerg, M.H.; Mohandas, N.; Raven Press: New York, 1994, pp. 205-215.
18. Bensinger, T.A.; Gillette, P.N. Hemolysis in sickle cell disease. Arch. Intern. Med., 1974, 133, 624-631.
19. Brittenham, G.M.; Schechter, A.N.; Noguchi, C.T. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood, 1985, 65, 183-189.
20. Allan, D.; Limbrick, A.R.; Thomas, P.; Westerman, M.P. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature, 1982, 295, 612-613.
21. Shet, A.S.; Aras, O.; Gupta, K.; Hass, M.J.; Rausch, D.J.; Saba, N.; Koopmeiners, L.; Key, N.S.; Hebbel, R.P. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood, 2003, 102, 2678-2683.
22. Hebbel, R.P.; Miller, W.J. Phagocytosis of sickle erythrocytes: immunologic and oxidative determinants of hemolytic anemia. Blood, 1984, 64, 733-741.
23. Wu, C.J.; Krishnamurti, L.; Kutok, J.L.; Biernacki, M.; Rogers, S.; Zhang, W.; Antin, J.H.; Ritz, J. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood, 2005, 106, 3639-3645. (Pubitemid 41609205)
24. Reiter, C.D.; Wang, X.; Tanus-Santos, J.E.; Hogg, N.; Cannon, R.O. 3rd,; Schechter, A.N.; Gladwin, M.T. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med., 2002, 8, 1383-1389.
25. Browne, P.; Shalev, O.; Hebbel, R.P. The molecular pathobiology of cell membrane iron: the sickle red cell as a model. Free Radic. Biol. Med., 1998, 24, 1040-1048. (Pubitemid 28186245)
26. Taylor, J.G. 6th,; Nolan, V.G.; Mendelsohn, L.; Kato, G.J.; Gladwin, M.T.; Steinberg, M.H. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One, 2008, 3, e2095.
27. Buehler, P.W.; Abraham, B.; Vallelian, F.; Linnemayr, C.; Pereira, C.P.; Cipollo, J.F.; Jia, Y.; Mikolajczyk, M.; Boretti, F.S.; Schoedon, G.; Alayash, A.I.; Schaer, D.J. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood, 2009, 113, 2578-2586.
28. Hebbel, R.P.; Morgan, W.T.; Eaton, J.W.; Hedlund, B.E. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Natl. Acad. Sci. USA, 1988, 85, 237-241.
29. Muller-Eberhard, U.; Javid, J.; Liem, H.H.; Hanstein, A.; Hanna, M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood, 1968, 32, 811-815.
30. Kato, G.J.; Gladwin, M.T.; Steinberg, M.H. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev., 2007, 21, 37-47.
31. Platt, O.S.; Brambilla, D.J.; Rosse, W.F.; Milner, P.F.; Castro, O.; Steinberg, M.H.; Klug, P.P. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med., 1994, 330, 1639-1644. (Pubitemid 124005049)
32. Miller, S.T.; Sleeper, L.A.; Pegelow, C.H.; Enos, L.E.; Wang, W.C.; Weiner, S.J.; Wethers, D.L.; Smith, J.; Kinney, T.R. Prediction of adverse outcomes in children with sickle cell disease. N. Engl. J. Med., 2000, 342, 83-89. (Pubitemid 30036599)
33. Cinel, I.; Opal, S.M. Molecular biology of inflammation and sepsis: a primer. Crit. Care Med., 2009, 37, 291-304.
34. Aird, W.C. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit. Care Med., 2001, 29, S28-34, discussion S34-35.
35. Kollander, R.; Solovey, A.; Milbauer, L.C.; Enenstein, J.; Abdulla, F.; Key, N.S.; Kelm, Jr. R.J.; Hebbel, R.P. NFκB component p50 in blood cells regulates endothelial tissue factor expression in sickle transgenic mice: Implications for the coagulopathy of sickle cell disease. Transl. Res., In press.
36. Belcher, J.D.; Marker, P.H.; Weber, J.P.; Hebbel, R.P.; Vercellotti, G.M. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 2000, 96, 2451-2459.
37. Esmon, C.T. The interactions between inflammation and coagulation. Br. J. Hematol., 2005, 131, 417-430.
38. Carden, D.L.; Granger, D.N. Pathophysiology of ischemia-reperfusion injury. J. Pathol., 2000, 190, 255-266.
39. Francis, Jr. R.P.; Hebbel, R.P. In Sickle Cell Disease: Basic Principles and Clinical Practice. Eds.; Embury, S.H.; Hebbel, R.P.; Mohandas, N.; Steinberg, M.H.; Raven Press: New York, 1994, 229-310.
40. Tomer, A.; Harker, L.A.; Kasey, S.; Eckman, J.R. Thrombogenesis in sickle cell disease. J. Lab. Clin. Med., 2001, 137, 398-407.
41. Guo, Y.; Uy, T.; Wandersee, N.J.; Scott, J.P.; Weiler, H.; Holzhauer, S.; Retherford, D.; Foster, T.; Hillery, C.A. The Protein C Pathway in Human and Murine Sickle Cell Disease: Alterations in Protein C, Thrombomodulin (TM), and Endothelial Protein C Receptor (EPCR) at Baseline and during Acute Vaso-occlusion. Blood, 2008, 112, 538a.
42. Key, N.S.; Slungaard, A.; Dandelet, L.; Nelson, S.C.; Moertel, C.; Styles, L.A.; Kuypers, F.A.; Bach, R.R. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood, 1998, 91, 4216-4223.
43. Solovey, A.; Gui, L.; Key, N.S.; Hebbel, R.P. Tissue factor expression by endothelial cells in sickle cell anemia. J. Clin. Invest., 1998, 101, 1899-1904. (Pubitemid 28226109)
44. Solovey, A.; Kollander, R.; Shet, A.; Milbauer, L.C.; Choong, S.; Panoskaltsis-Mortari, A.; Blazar, B.R.; Kelm, Jr. R.J.; Hebbel, R.P. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 2004, 104, 840-846.
45. Adedeji, M.O.; Cespedes, J.; Allen, K.; Subramony, C.; Hughson, M.D. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch. Pathol. Lab. Med., 2001, 125, 1436-1441. (Pubitemid 33070181)
46. Wun, T.; Cordoba, M.; Rangaswami, A.; Cheung, A.W.; Paglieroni, T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin. Lab. Hematol., 2002, 24, 81-88. (Pubitemid 35013546)
47. McGregor, L.; Martin, J.; McGregor, J.L. Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodeling and thrombosis. Front. Biosci., 2006, 11, 830-837.
48. Solovey, A.; Kollander, R.; Milbauer, L.C.; Abdulla, F.; Chen, Y.; Lefer, D.J.; Kelm, Jr. R.J.; Hebbel, R.P. eNOS and NO regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. Am. J. Hematol., In Press.
49. Steinberg, S.F. The cardiovascular actions of protease-activated receptors. Mol. Pharmacol., 2005, 67, 2-11.
50. Setty, B.N.Y.; Zhang, J.; Kulkarni, S.; Wang, X.; Key, N.S.; Gladwin, M.T.; Stuart, M.J. Pathologic implications of type-II phosphatidylserine (PS)-positive erythrocytes in patients with sickle cell disease. 29th Annual Meeting of the National Sickle Cell Disease Program, April 8-12, 2006, Memphis, TN. Abstract 53.
51. van Gils, J.M.; Zwaginga, J.J.; Hordijk, P.L. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J. Leukoc. Biol., 2009, 85, 195-204.
52. Westerman, M.P.; Green, D.; Gilman-Sachs, A.; Beaman, K.; Freels, S.; Boggio, L.; Allen, S.; Schlegel, R.; Williamson, P. Coagulation changes in individuals with sickle cell trait. Am. J. Hematol., 2002, 69, 89-94. (Pubitemid 34111159)
53. Austin, H.; Key, N.S.; Benson, J.M.; Lally, C.; Dowling, N.F.; Whitsett, C.; Hooper, W.C. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood, 2007, 110, 908-912.
54. Wood, K.C.; Granger, D.N. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin. Exp. Pharmacol. Physiol., 2007, 34, 926-932. (Pubitemid 47083959)
55. Sultana, C.; Shen, Y.; Rattan, V.; Johnson, C.; Kalra, V.K. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood, 1998, 92, 3924-3935.
56. Wood, K.C.; Hebbel, R.P.; Granger, D.N. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J., 2005, 19, 989-991.
57. Houston, M.; Estevez, A.; Chumley, P.; Aslan, M.; Marklund, S.; Parks, D.A.; Freeman, B.A. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J. Biol. Chem., 1999, 274, 4985-4994. (Pubitemid 129501516)
58. Aslan, M.; Freeman, B.A. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease - mechanisms and consequences. Cell Mol. Biol. (Noisy-le-grand), 2004, 50, 95-105.
59. Wood, K.C.; Hebbel, R.P.; Lefer, D.J.; Granger, D.N. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic. Biol. Med., 2006, 40, 1443-1453.
60. Baldus, S.; Eiserich, J.P.; Brennan, M.L.; Jackson, R.M.; Alexander, C.B.; Freeman, B.A. Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic. Biol. Med., 2002, 33, 1010.
61. Kaul, D.K.; Hebbel, R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. of Clin. Invest., 2000, 106, 411-420.
62. Manfredini, V.; Lazzaretti, L.L.; Griebeler, I.H.; Santin, A.P.; Brandão, V.D.; Wagner, S.; Castro, S.M.; Peralba Mdo, C.; Benfato, M.S. Blood antioxidant parameters in sickle cell anemia patients in steady state. J. Natl. Med. Assoc., 2008, 100, 897-902.
63. Chiu, D.; Lubin, B. Abnormal vitamin E and glutathione peroxidase levels in sickle cell anemia: evidence for increased susceptibility to lipid peroxidation in vivo. J. Lab. Clin. Med., 1979, 94, 542-548. (Pubitemid 10210886)
64. Belcher, J.D.; Marker, P.H.; Geiger, P.; Girotti, A.W.; Steinberg, M.H.; Hebbel, R.P.; Vercellotti, G.M. Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. J. Lab. Clin. Med., 1999, 133, 605-612.
65. Nath, K.A.; Grande, J.P.; Haggard, J.J.; Croatt, A.J.; Katusic, Z.S.; Solovey, A.; Hebbel, R.P. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am. J. Pathol., 2001, 158, 893-903.
66. Jison, M.L.; Munson, P.J.; Barb, J.J.; Sufffredini, A.F.; Talwar, S.l.; Logun, C.; Raghavachari, N.; Beigel, J.H.; Shelhamer, J.H.; Danner, R.L.; Gladwin, M.T. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood, 2004, 104, 270-280.
67. Osarogiagbon, U.R.; Choong, S.; Belcher, J.D.; Vercellotti, G.M.; Paller, M.S.; Hebbel, R.P. Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320. (Pubitemid 30456487)
68. Belcher, J.D.; Mahaseth, H.; Welch, T.E.; Otterbein, L.E.; Hebbel, R.P.; Vercellotti, G.M. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J. Clin. Invest., 2006, 116, 808-816.
69. Navab, M.; Fogelman, A.M.; Berliner, J.A.; Territo, M.C.; Demer, L.L.; Frank, J.S.; Watson, A.D.; Edwards, P.A.; Lusis, A.J. Pathogenesis of atherosclerosis. Am. J. Cardiol., 1995, 76, 18C-23C.
70. Krajewski, M.L.; Hsu, L.L.; Gladwin, M.T. The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology. Am. J. Physiol. Heart. Circ. Physiol., 2008, 295, H4-H7.
71. Hebbel, R.P. Adhesion of sickle red cells to endothelium: myths and future directions. Transfus. Clin. Biol., 2008, 15, 14-18.
72. Hebbel, R.P.; Boogaerts, M.A.; Eaton, J.W.; Steinberg, M.H. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N. Engl. J. Med., 1980, 302, 992-995.
73. Hebbel, R.P.; Yamada, O.; Moldow, C.F.; Jacob, H.S.; White, J.G.; Eaton, J.W. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J. Clin. Invest., 1980, 65, 154-160.
74. Kaul, D.K.; Fabry, M.E. In vivo studies of sickle red blood cells. Microcirculation, 2004, 11, 153-165. (Pubitemid 39619076)
75. Solovey, A.A.; Solovey, A.N.; Harkness, J.; Hebbel, R.P. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood, 2001, 97, 1937-1941. (Pubitemid 32239070)
76. Wagner, D.D.; Frenette, P.S. The vessel wall and its interactions. Blood, 2008, 111, 5271-5281.
77. Turhan, A.; Weiss, L.A.; Mohandas, N.; Coller, B.S.; Frenette, P.S. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl. Acad. Sci. USA, 2002, 99, 3047-3051.
78. Matsui, N.M.; Varki, A.; Embury, S.H. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood, 2002, 100, 3790-3796.
79. Lipowsky, H.H.; Williams, M.E. Shear rate dependency of red cell sequestration in skin capillaries in sickle cell disease and its variation with vasoocclusive crisis. Microcirculation, 1997, 4, 289-301.
80. Kalambur, V.S.; Mahaseth, H.; Bischof, J.C.; Kielbik, M.C.; Welch, T.E.; Vilbäck, A.; Swanlund, D.J.; Hebbel, R.P.; Belcher, J.D.; Vercellotti, G.M. Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy. Am. J. Hematol., 2004, 77, 117-125. (Pubitemid 39281854)
81. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359, 843-845.
82. Solovey, A.; Gui, L.; Ramakrishnan, S.; Steinberg, M.H.; Hebbel, R.P. Sickle cell anemia as a possible state of enhanced antiapoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood, 1999, 93, 3824-3830.
83. Belhassen, L.; Pelle, G.; Sediame, S.; Bachir, D.; Carville, C.; Bucherer, C.; Lacombe, C.; Galacteros, F.; Adnot, S. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood, 2001, 97, 1584-1589. (Pubitemid 32217221)
84. Gladwin, M.T.; Crawford, J.H.; Patel, R.P. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic. Biol. Med., 2004, 36, 707-717. (Pubitemid 38264415)
85. Gladwin, M.T.; Schechter, A.N.; Ognibene, F.P.; Coles, W.A.; Reiter, C.D.; Schenke, W.H.; Csako, G.; Waclawiw, M.A.; Panza, J.A.; Cannon, R.O. 3rd. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation, 2003, 107, 271-278.
86. Eberhardt, R.T.; McMahon, L.; Duffy, S.J.; Steinberg, M.H.; Perrine, S.P.; Loscalzo, J.; Coffman, J.D.; Vita, J.A. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am. J. Hematol., 2003, 74, 104-111.
87. Harada, H.; Pavlick, K.P.; Hines, I.N.; Hoffman, J.M.; Bharwani, S.; Gray, L.; Wolf, R.E.; Grisham, M.B. Selected contribution: Effects of gender on reduced-size liver ischemia and reperfusion injury. J. Appl. Physiol., 2001, 91, 2816-2822. (Pubitemid 33108049)
88. Kaul, D.K.; Zhang, X.; Dasgupta, T.; Fabry, M.E. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H39-H47.
89. Ou. J.; Ou, Z.; Jones, D.W.; Holzhauer, S.; Hatoum, O.A.; Ackerman, A.W.; Weihrauch, D.W.; Gutterman, D.D.; Guice, K.; Oldham, K.T.; Hillery, C.A.; Pritchard, Jr. K.A. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation, 2003, 107, 2337-2341.
90. Hsu, L.L.; Champion, H.C.; Campbell-Lee, S.A.; Bivalacqua, T.J.; Manci, E.A.; Diwan, B.A.; Schimel, D.M.; Cochard, A.E.; Wang, X.; Schechter, A.N.; Noguchi, C.T.; Gladwin, M.T. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood, 2007, 109, 3088-3098.
91. Nath, K.A.; Katusic, Z.S.; Gladwin, M.T. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation, 2004, 11, 179-193.
92. Kaul, D.K.; Liu, X.D.; Fabry, M.E.; Nagel, R.L. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am. J. Physiol. Heart Circ. Physiol., 2000, 278, H1799-H1806.
93. Nath, K.A.; Shah, V.; Haggard, J.J.; Croatt, A.J.; Smith, L.A.; Hebbel, R.P.; Katusic, Z.S. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279, R1949-R1955.
94. Aslan, M.; Freeman, B.A. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic. Biol. Med., 2007, 43, 1469-1483. (Pubitemid 47615401)
95. Wood, K.C.; Hsu, L.L.; Gladwin, M.T. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic. Biol. Med., 2008, 44, 1506-1528.
96. Schnog, J.B.; Teerlink, T.; van der Dijs, F.P.; Duits, A.J.; Muskiet, F.A.; CURAMA Study Group. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann. Hematol., 2005, 84, 282-286.
97. Förstermann, U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol. Chem., 2006, 387, 1521-1533. (Pubitemid 44837576)
98. Katusic, Z.S.; d'Uscio, L.V.; Nath, K.A. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci., 2009, 30, 48-54.
99. Morris, C.R.; Kuypers, F.A.; Larkin, S.; Vichinsky, E.P.; Styles, L.A. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J. Pediatr. Hematol. Oncol., 2000, 22, 515-520.
100. Morris, C.R.; Kato, G.J.; Poljakovic, M.; Wang, X.; Blackwelder, W.C.; Sachdev, V.; Hazen, S.L.; Vichinsky, E.P.; Morris, Jr. S.M.; Gladwin, M.T. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA, 2005, 294, 81-90. (Pubitemid 41002842)
101. Juncos, J.P.; Grande, J.P.; Murali, N.; Croatt, A.J.; Juncos, L.A.; Hebbel, R.P.; Katusic, Z.S.; Nath, K.A. Anomalous renal effects of tin protoporphyrin in a murine model of sickle cell disease. Am. J. Pathol., 2006, 169, 21-31.
102. Nath, K.A.; Grande, J.P.; Croatt, A.J.; Frank, E.; Caplice, N.M.; Hebbel, R.P.; Katusic, Z.S. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am. J. Pathol., 2005, 166, 963-972.
103. Sabaa, N.; de Franceschi, L.; Bonnin, P.; Castier, Y.; Malpeli, G.; Debbabi, H.; Galaup, A.; Maier-Redelsperger, M.; Vandermeersch, S.; Scarpa, A.; Janin, A.; Levy, B.; Girot, R.; Beuzard, Y.; Leboeuf, C.; Henri, A.; Germain, S.; Dussaule, J.C.; Tharaux, P.L. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J. Clin. Invest., 2008, 118, 1924-1933.
104. Lin, Y.; Weisdorf, D.J.; Solovey, A.; Hebbel, R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest., 2000, 105, 71-77. (Pubitemid 30036389)
105. Chang Milbauer, L.; Wei, P.; Enenstein, J.; Jiang, A.; Hillery, C.A.; Scott, J.P.; Nelson, S.C.; Bodempudi, V.; Topper, J.N.; Yang, R.B.; Hirsch, B.; Pan, W.; Hebbel, R.P. Genetic endothelial systems biology of sickle stroke risk. Blood, 2008, 111, 3872-3879.
106. Sebastiani, P.; Ramoni, M.F.; Nolan, V.; Baldwin, C.T.; Steinberg, M.H. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat. Genet., 2005, 37, 435-440. (Pubitemid 40490496)
107. Hoppe, C.; Klitz, W.; D'Harlingue, K.; Cheng, S.; Grow, M.; Steiner, L.; Noble, J.; Adams, R.; Styles, L.; Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke, 2007, 38, 2241-2246.
108. Nolan, V.G.; Baldwin, C.; Ma, Q.; Wyszynski, D.F.; Amirault, Y.; Farrell, J.J.; Bisbee, A.; Embury, S.H.; Farrer, L.A.; Steinberg, M.H. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anemia. Br. J. Hematol., 2005, 128, 266-272.
109. Ashley-Koch, A.E.; Elliott, L.; Kail, M.E.; De Castro, L.M.; Jonassaint, J.; Jackson, T.L.; Price, J.; Ataga, K.I.; Levesque, M.C.; Weinberg, J.B.; Orringer, E.P.; Collins, A.; Vance, J.M.; Telen, M.J. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood, 2008, 111, 5721-5726.
110. Steinberg, M.H. Genetic etiologies for phenotypic diversity in sickle cell anemia. Scientific WorldJournal, 2009, 9, 46-67.
111. Sebastiani, P.; Timofeev, N.; Dworkis, D.A.; Perls, T.T.; Steinberg, M.H. Genome-wide association studies and the genetic dissection of complex traits. Am. J. Hematology. 2009, E-pub (http://www3.interscience.wiley.com/cgi-bin/home/ 35105).
112. Sebastiani, P.; Nolan, V.G.; Baldwin, C.T.; Abad-Grau, M.M.; Wang, L.; Adewoye, A.H.; McMahon, L.C.; Farrer, L.A.; Taylor, J.G.; Kato, G.J.; Gladwin, M.T.; Steinberg, M.H. A network model to predict the risk to death in sickle cell disease. Blood, 2007, 111, 2727-2735. (Pubitemid 47523196)
113. King, S.B. Nitric oxide production from hydroxyurea. Free Radic. Biol. Med., 2004, 37, 737-744.
114. Lanzkron, S.; Strouse, J.J.; Wilson, R.; Beach, M.C.; Haywood, C.; Park, H.; Witkop, C.; Bass, E.B.; Segal, J.B. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann. Intern. Med., 2008, 148, 939-955. (Pubitemid 351860826)
115. Kato, G.J.; Gladwin, M.T. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA, 2008, 300, 2638-2646.
116. Browne, P.V.; Shalev, O.; Kuypers, F.A.; Brugnara, C.; Solovey, A.; Mohandas, N.; Schrier, S.L.; Hebbel, R.P. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J. Clin. Invest., 1997, 100, 1459-1464.
117. Ou, Z.; Ou, J.; Ackerman, A.W.; Oldham, K.T.; Pritchard, Jr. K.A. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation, 2003, 107, 1520-1524.
118. Sasaki, J.; Waterman, M.R.; Cottam, G.L. Decreased apolipoprotein A-I and B content in plasma of individuals with sickle cell anemia. Clin. Chem., 1986, 32, 226-227.
119. Yuditskaya, S.; Tumblin, A.; Hoehn, G.T.; Wang, G.; Drake, S.K.; Xu, X.; Ying, S.; Chi, A.H.; Remaley, A.T.; Shen, R.F.; Munson, P.J.; Suffredini, A.F.; Kato, G.J. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood, 2009, 113, 1122-1128.
120. Beckman, J.A.; Creager, M.A. The nonlipid effects of statins on endothelial function. Trends Cardiovasc. Med., 2006, 16, 156-162. (Pubitemid 43867329)
121. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, Jr. A.M.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359, 2195-2207.
122. Dasgupta, T.; Hebbel, R.P.; Kaul, D.K. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic. Biol. Med., 2006, 41, 1771-1780.
123. Vanhaecke, T.; Papeleu, P.; Elaut, G.; Rogiers, V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem., 2004, 11, 1629-1643. (Pubitemid 38735799)
124. Hebbel, R.P.; Vercellotti, G.M.; Pace, B.S.; Solovey, A.N.; Kollander, R.; Abanonu, C.F.; Nguyen, J.; Belcher, J.; Abdulla, F.; Osifuye, S.; Eaton, J.W.; Kelm, Jr. R.J.; Slungaard, A. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Submitted.